Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RTA 408 0.5%, 1%, 3% · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | PLACEBO_COMPARATOR | RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days |
| Part B | EXPERIMENTAL | Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, \~100 cm2 surface area) |
| Part C | EXPERIMENTAL | 3% RTA 408 lotion applied to skin twice daily for 28 days (\~500 cm2 surface area) |
| Name | Type | Description |
|---|---|---|
| RTA 408 Lotion 0.5%, 1%, 3% | DRUG | - |
| Lotion vehicle/placebo | DRUG | - |
Inclusion Criteria: 1. Subjects must voluntarily give written informed consent and agree to comply with visit schedule including willingness to remain at the study site; 2. Subjects must be adults (male or female), ages 18 to 65, inclusive; 3. Subjects must have healthy skin on which reddening can ...
RTA 408 0.5%, 1%, 3% is a small molecule being studied for use in healthy volunteers. It is currently in Phase 1 clinical development as a lotion formulation. The investigational drug is being evaluated in a clinical trial to assess its safety and tolerability in healthy individuals.
RTA 408 0.5%, 1%, 3% is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. Biogen is conducting clinical research on this investigational small molecule lotion for use in healthy volunteers.
RTA 408 0.5%, 1%, 3% is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, with a total enrollment of 109 participants.
RTA 408 0.5%, 1%, 3% was studied in a completed Phase 1 clinical trial identified as NCT02029716, titled 'RTA 408 Lotion in Healthy Volunteers'. This randomized, double-blind, placebo-controlled trial enrolled 109 healthy adult participants in the United States.
RTA 408 0.5%, 1%, 3% refers to specific concentrations of the investigational drug RTA 408 formulated as a lotion. The clinical trial NCT02029716 evaluated these three concentrations in healthy volunteers. The drug is being developed by Biogen Inc.